Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program

Core Viewpoint - Catalyst Pharmaceuticals has announced a new share repurchase program to buy back up to $200 million of its common stock between October 1, 2025, and December 31, 2026, reflecting confidence in its financial position and long-term growth strategy [1][2]. Financial Position - As of June 30, 2025, Catalyst reported over $650 million in cash and cash equivalents with no funded debt, indicating a strong balance sheet [2]. - The company has demonstrated solid operating results and significant cash flow generation, which supports the execution of the share repurchase program without hindering business development [2]. Share Repurchase Program - The share repurchase may be executed through various methods, including open market or privately negotiated purchases, with the timing and amount depending on stock price and market conditions [2]. - Catalyst is not obligated to repurchase a specific number of shares, and the program may be suspended or terminated at any time [2]. Company Overview - Catalyst Pharmaceuticals is focused on developing and commercializing novel medicines for rare diseases, with a commitment to patient care and accessibility [3]. - The company has been recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America's Fastest-Growing Companies [3].